Patients with heart failure (HF) with reduced (HFrEF) or preserved (HFpEF) ejection fraction demonstrate an increased ventilatory equivalent for carbon dioxide (V E /VCO 2 ) slope. The physiological correlates of theV E /VCO 2 slope remain unclear in the two HF phenotypes. We hypothesized that changes in the physiological dead space to tidal volume ratio (V D /V T ) and arterial CO 2 tension (PaCO 2 ) differentially contribute to theV E 
Introduction
A steep slope in the ventilatory equivalent for carbon dioxide (V E /VCO 2 ) as quantified during cardiopulmonary exercise testing (CPET) demonstrates robust prognostic power in heart failure (HF) patients with reduced (HFrEF) or preserved (HFpEF) ejection fraction.
1 -4 Ventilatory inefficiency is suggested to accompany an excessive rate-mediated rise inV E /VCO 2 slope, which is likely to be both a consequence of and key contributor to exercise intolerance in HF. 2 -5 In this context, despite the broad clinical and research use of theV E /VCO 2 slope to phenotype the magnitude of exercise ventilatory inefficiency in HF, the physiological understanding of this index has not been clearly defined in patients with HFrEF or HFpEF.
TheV E /VCO 2 slope is determined by dynamic coupling of gas exchange and haemodynamics reflecting pulmonary, cardiac, musculoskeletal and nervous system responses to exercise. 4, 6 -8 'Ideal' alveolar gas and air equations implicate the proportion of tidal volume distributed to physiological dead space (V D /V T ), accompanied by mechanisms underpinning the regulation of arterial carbon dioxide tension (PaCO 2 ) as key contributors to theV E /VCO 2 slope. 4, 6, 7, 9 Although an increasedV E /VCO 2 slope is likely to be the consequence of integrated factors including wasted alveolar ventilation (V A ), atelectasis and/or impaired neural ventilatory control, there is controversy as to which event is the principal mediator in HFrEF, 4, 7, 9, 10 and even less information is available on this topic in HFpEF. Further complicating this discussion is evolving knowledge of the unique characteristics that unequivocally define the HFpEF phenotype. 2, 3, 5, 11, 12 Guazzi et al. 4 demonstrated that a highV E /VCO 2 slope from rest to peak exercise is predictive of survival in HFrEF. In findings similar to data collected by Woods et al. 7 during submaximal exercise, Guazzi et al. 4 attributed an increasedV E /VCO 2 slope to the influences of impaired mechanisms of ventilatory control (e.g. low PaCO 2 regulatory set-points) accompanied by contributions from elevated V D /V T . In contrast, without observations from specific tests of ventilatory control, Sullivan et al. 9 and others 10 suggest that ventilatory control related to regulation of PaCO 2 is intact in HFrEF, whereas abnormal physiological haemodynamic factors are more likely to be present in this population.
As a necessary hypothesis-generating step towards advancing the understanding and interpretation of theV E /VCO 2 slope in HF, this study aimed to demonstrate how theV E /VCO 2 slope is related to changes in V D /V T and PaCO 2 during CPET in patients with HFrEF or HFpEF. We hypothesized that increased V D /V T accompanied by decreased PaCO 2 would differentially explain the rise in theV E /VCO 2 slope in HFrEF compared with HFpEF.
Methods

Participants
Patients with HFrEF or HFpEF (n = 59) were referred by their primary cardiologist for CPET as part of a comprehensive HF evaluation at the Mayo Clinic (Rochester, MN, USA). Using the European Society of Cardiology criteria, 13 we studied 32 subjects with HFrEF [left ventricular ejection fraction (LVEF) ≤40%] and 27 subjects with HFpEF (LVEF >50%). Patient characteristics are outlined in Table 1 .
Patients were excluded if they demonstrated any of the following: significant coronary artery disease (stenosis ≥50%); cor pulmonale; diagnosed pulmonary disease independent or secondary to HF; primary renal or hepatic disease; valvular heart disease (any stenosis, greater than mild regurgitation, etc.); hypertrophic or infiltrative cardiomyopathy; constrictive pericarditis, and deep vein thrombosis. All aspects of this study were approved by the Mayo Clinic Institutional Review Board and conformed to the principles outlined in the Declaration of Helsinki. were used to assess LVEF, morphology and function, as well as early transmitral flow velocity (E), late transmitral flow velocity (A), E/A ratio, early diastolic mitral annular velocity (e'), peak E/e' ratio, and left atrial volumes ( Table 1) . 13 
Echocardiography
Protocol for cardiopulmonary exercise testing
Patients participated in CPET in the morning in a fasted state while remaining on standard pharmacological therapy. Patients exercised in a semi-recumbent position at an initial workload of 20 W while pedalling at 60-65 r.p.m., thereafter increasing by 10-W every 3 min until volitional fatigue was achieved. Heart rate and rhythm were continuously monitored using a 12-lead electrocardiogram.
Ventilation and gas exchange
Breath-by-breath open-circuit spirometry (CPX/D; MGC Diagnostics Corp., St Paul, MN, USA) was used to continuously collect ventilation and gas exchange data throughout CPET. The final 30 s of rest and the final completed stage [i.e. peak pulmonary oxygen uptake (VO 2peak )] were used for data analyses. Data were acquired for the variablesVO 2 , VCO 2 , respiratory exchange ratio (RER), respiratory rate (f B ), V T ,V E , end-tidal CO 2 tension (P ET CO 2 ) and end-tidal O 2 tension (P ET O 2 ). The percentage of predictedVO 2peak was calculated from Hansen et al.
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Arterial gas measurement and parameters
Continuous monitoring and periodic sampling of arterial blood gases were conducted using a standard technique via the percutaneous insertion of a 20-gauge catheter at the left radial artery. Arterialized blood was drawn into heparinized 3-mL glass syringes to approximately align with breath-by-breath periods (i.e. final ∼30 s of each CPET stage), with the final draw of the last completed stage used to describe peak exercise. Arterialized samples were rolled, chilled on ice and immediately sent to the institution's core laboratory where data on PaCO 2 , oxygen tension (PaO 2 ), arterial pH (pHa) and oxygen saturation (SaO 2 ) were obtained using standard processing techniques. From these measurements, we used standard physiological and blood biochemical equations (see Appendix) to derive bicarbonate (HCO 3 − ) and base excess (BE) values of arterialized blood.
Derived ventilation and gas exchange parameters
By using arterialized gas measurements combined with acquired basic ventilatory and gas exchange responses, 'ideal' alveolar gas and air equations with associated parameters were applied to calculateV A , alveolar volume (V A ), alveolar CO 2 tension (PACO 2 ), alveolar O 2 tension (PAO 2 ), alveolar-to-arterial O 2 difference (PA-aO 2 ), indirect simplified estimate of whole-lung diffusing capacity for O 2 (DLO 2 ) via Fick's law of diffusion, and V D ventilation (V D ) (see Appendix), 4, 6 -10 where V D /V T equalled:
where 863 converts gas concentration to partial pressure while correcting for the fact thatVCO 2 is expressed as a dry gas volume at standard temperature (0 ∘ C), pressure (760 mmHg) and dry (0% water 9.9 ± 1.6 9.5 ± 1.6 10.2 ± 1.6 0.06 Posterior wall thickness, mm 9.8 ± 1.7 9.7 ± 1.5 9.9 ± 1.9 0.96 ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LA, left atrium; LV, left ventricle; NYHA, New York Heart Association; SD, standard deviation;VO 2 , oxygen consumption.
vapour) (STPD), whereas ventilation is expressed as a wet gas volume at body temperature, pressure and saturation (BTPS). Mixed-expired CO 2 (PECO 2 ) equalled the quotient of 863 anḋ V E /VCO 2 . 15 All data from rest to peak exercise were used to calculate theV E /VCO 2 slope using linear regression, which provided optimal data interpretability and temporal consistency across participants. 16 
Statistical analyses
Parametric data are presented as the mean ± standard deviation (SD). Between-group baseline differences were compared using independent Student's t-tests for parametric data or 2 tests for categorical variables. Repeated-measures analysis of variance (ANOVA) models with group-by-time interaction terms were used to test betweenand within-group differences at rest and peak exercise. When F-tests from group-by-time interaction terms were significant, post hoc Tukey-Kramer tests were used to assess between and within pairwise differences.
Ordinary least squares univariate linear regressions were used to test relationships between dependent (ordinate,V E /VCO 2 slope) and independent (abscissa, V D /V T , PaCO 2 , etc.) variables. The coefficient of determination (R 2 ) and regression equations (y est = a + bx) were computed from these models. Interpretation of R 2 was based on the standards proposed by Cohen, 17 where R 2 values of 0.02, 0.15 and ≥0.25 indicate modest, moderate and strong coefficients, respectively. Two-tailed significance was determined using an alpha level set at 0.05. Statistical analyses were performed using SAS Version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Participant characteristics
Both the HFrEF and HFpEF groups demonstrated age, sex distribution and LVEF profiles consistent with currently recognized clinical phenotypes ( Table 1) . Despite a greater percentage of predictedVO 2peak in HFpEF vs. HFrEF, there were no differences iṅ VO 2peak (mL/kg/min). New York Heart Association (NYHA) and Weber-Janicki functional classifications aligned in HFpEF, and to a lesser extent in HFrEF. Compared with HFpEF, haemoglobin (Hb) was higher in HFrEF, whereas creatinine and estimated glomerular filtration rate (eGFR) were similar. The frequencies of therapies including ACE inhibitors, beta-blockers (in the HFrEF group, 6 and 22 patients were on non-selective and 1 -selective beta-blockers, respectively; in the HFpEF group: 17 of 27 patients were on 1 -selective beta-blockers), digoxin and diuretics were higher in the HFrEF group than in the HFpEF group. Resting echocardiography indicated increased left ventricular filling pressures in HFrEF and HFpEF. Participants completed all aspects of this study with no demonstration of adverse events (i.e. no signs/symptoms of pulmonary embolism, which may contribute to impaired ventilatory function).
Workload and basic ventilation and gas exchange
RestingVO 2 ,VCO 2 , RER,V E , RR, V T , P ET O 2 and PECO 2 /P ET CO 2 were similar between the groups, whereas P ET CO 2 and PECO 2 were lower in the HFrEF than in the HFpEF group ( Table 2) . Despite no differences in peak workload and RER,VO 2 andVCO 2 were lower in HFrEF than in HFpEF, whereas differences inV E /VCO 2 , P ET CO 2 and PECO 2 persisted from rest. Except forV E /VCO 2 (↓HFpEF), P ET CO 2 (↓HFrEF) and PECO 2 (↑HFpEF), changes in other metrics from rest to peak exercise were similar across the HFrEF and HFpEF groups ( Table 2) .
Alveolar equation and blood biochemistry parameters
With the exception of resting V D /V T , which was lower in HFpEF than in HFrEF (Figure 1 ), parameters associated with alveolar equations or blood biochemistry were similar between the groups ( Table 3) . By contrast, consistent with the higherV E /VCO 2 slope in HFrEF ( Figure 1A) , the HFrEF group demonstrated higher V D , V D and V D /V T ( Figure 1B) , as well as lower PaCO 2 ( Figure 1C ) and PACO 2 accompanied by higher pHa at peak exercise than the HFpEF group ( Table 3) . The absence of between-group differences for other metrics at rest persisted to peak exercise. within-group differences from rest to peak exercise, the HFrEF and HFpEF groups demonstrated similar directional changes for the variables in Table 3 other than for PaO 2 , which increased within HFrEF but not within HFpEF.
In subanalyses including only the HFrEF (n = 22) and HFpEF (n = 17) patients on 1 -blockers, between-within differences iṅ V E /VCO 2 slope (F = 13.7, P < 0.01), V D /V T (F = 20.7, P < 0.01), and PaCO 2 (F = 5.12, P < 0.01) mirrored outcomes illustrated in Figure 1(A-C) . Within HFpEF, there were no differences in thė V E /VCO 2 slope (P = 0.96), peak exercise V D /V T (P = 0.69) and peak exercise PaCO 2 (P = 0.90) between patients on and those not on 1 -blockers.
Predictors of theV E /VCO 2 slope
Resting LVEF was unrelated toV E /VCO 2 slope when stratified by HF group (Figure 1D) , whereas data analysed for all HF patients resulted in a modest relationship (y = −0.21x + 48; R 2 = 0.16, P = 0.01). In comparison, peak exercise V D /V T and PaCO 2 strongly explained the variance inV E /VCO 2 slope across all HF subjects ( Figure 1E, F) .
Consistent with plots of HFrEF vs. HFpEF in Figure 1 (E, F), the unique contributions from each group to pooled regressions are illustrated in detail in Figure 2 . Although decreasing PaCO 2 strongly explained the variance associated with increasingV E /VCO 2 slope in HFrEF ( Figure 2C ), V D /V T was more strongly related to the elevatedV E /VCO 2 slope in HFpEF ( Figure 2B ). Although there was significant linearity between increasing V D /V T andV E /VCO 2 slope in HFrEF (Figure 2A) , as well as between PaCO 2 andV E /VCO 2 slope in HFpEF (inverse relationship) ( Figure 2D ), the degrees of variance explained in Figure 2 Finally, although increasingV D and PAO 2 accompanied by decreasing PACO 2 demonstrated significant linearity with the increasingV E /VCO 2 slope in HFrEF and HFpEF, in an inverse manner, HCO 3 − and BE explained the variance in theV E /VCO 2 slope in HFrEF, but did not do so in HFpEF ( Table 4) .
Discussion
These data suggest that an increasedV E /VCO 2 slope in both HFrEF and HFpEF patients is fundamentally linked to elevated V D /V T accompanied by altered regulation of PaCO 2 during CPET. Both the HFrEF and HFpEF groups demonstratedV E /VCO 2 slopes at levels consistent with a worsened prognosis.
1 -4 However, moderate-to-strong relationships between increasing V D /V T and decreasing PaCO 2 with a risingV E /VCO 2 slope differed in HFrEF compared with HFpEF. Decreasing PaCO 2 at peak exercise in HFrEF explained more than twice the variance in theV E /VCO 2 4, 7, 18 -21 Energy demand that exceeds oxidative capabilities leads to a marked rise in CO 2 production followed by an acidotic blood milieu if accumulated CO 2 blood content is not adequately compensated. 6, 8 In healthy adults, metabolic-driven production of CO 2 leads to intrinsic activation of pathways relating to mechanisms of HCO 3 − formation accompanied by increased ventilation. The timely coordination of these events during exercise functions well as a buffering mechanism (Hb binds H + ) to help maintain blood acid-base balance while facilitating decreased blood CO 2 content as Na + binds HCO 3 − (and to a lesser extent Hb binds CO 2 ) to be transported to the pulmonary system for expiration. However, it remains unclear how these interconnected compensatory mechanisms of breathing and acid-base buffering equilibrate in conditions in which both the rate and absolute level of CO 2 accumulation in blood may become accelerated, such as might occur in HF.
Patients with HF demonstrate greater reliance on non-oxidative energy demand, which leads to increased CO 2 production. 20 Both HFrEF and HFpEF may demonstrate skeletal muscle fibre shifts 
drop in HCO 3
− from rest to peak exercise accompanied by negative BE is consistent with the presence of metabolic acidosis and base deficit. 6, 8, 22, 23 The concurrent decrease in PaCO 2 linked to patterned responses in HCO 3 − , BE,V E and pHa is consistent with the notion that ventilatory control pathways may function at an abnormally high gain coupled with a low PaCO 2 (apnoeic) set-point in HF. 4 In this context, the present group and others have demonstrated that metabolically activated muscle afferents during exercise contribute to increased ventilation andV E /VCO 2 slope in HFrEF. 18, 19, 21 Although this study did not include tests of muscle afferent activation linked to ventilatory function, if we assume that skeletal muscle pathology occurs secondary to HF, 20 this musculoskeletal neural pathway connecting systemic blood biochemical changes to brainstem centres of ventilatory control is a candidate mechanism contributing to an increasedV E /VCO 2 slope in HF.
Although PaCO 2 and V D /V T are interrelated, the shift in the relationship between an increasedV E /VCO 2 slope from PaCO 2 in HFrEF to V D /V T in HFpEF suggests there may have been an influence of sub-clinical pathology of mechanical and/or structural pulmonary features on the increasedV E /VCO 2 slope in HFpEF. 4, 9, 15, 24 However, if sub-clinical pulmonary disease occurring independently or secondary to HF were to have been present in HFpEF, we hypothesize that although the inhomogeneous distribu- . Even with the potential for moderately reduced (∼20% drop from normal) lung diffusing capacity in HFpEF, 24 because of distinct properties of CO 2 (e.g. high blood solubility and diffusion rate), it could be suggested that any perfusion (V A /Q >0.0) of normally ventilated alveoli would result in little interference in CO 2 transfer. 6, 8 In contrast, it is likely that with an inhomogeneous distribution ofV A /Q <1.0,V A and DLO 2 throughout the lungs, the effects of venous admixture and moderately reduced gas transfer will nominally influence PaCO 2 while effectively diluting arterial O 2 content, and increase PA-aO 2 . In as much as HFpEF demonstrated alignment between PaCO 2 and PACO 2 , suggesting no impairment in CO 2 diffusing capacity, PA-aO 2 simultaneously extended beyond normal limits. 6, 8 These combined observations are consistent with the 
Limitations
Information regarding the long-term prognostic translation of the present observations is not yet available in this limited sample size of HF patients, and causality cannot be deduced from these data. The increasedV E /VCO 2 slope in the HFpEF group in this study represents the higher limit in this population. A possible explanation for this observation is a secondary effect of ageing as these data are consistent with the findings of Haykowski et al. 5 direct correlation between body mass index and degree of diastolic dysfunction independent of comorbidities commonly recognized in HFpEF. 25 Although this study did not include age-and body size-matched controls with respect to each HF group, elucidating the independent influences of ageing and obesity on ventilatory inefficiency is important in this line of study as both factors contribute to the HFpEF phenotype.
Discussions regarding the influence of pulmonary perfusion on theV E /VCO 2 slope and V D /V T provide interpretations that generate hypotheses without direct measurements of central haemodynamics. Despite this limitation, the study design based upon 'ideal' alveolar equations accounts for cardiopulmonary haemodynamic interactions in addition to influences of peripheral perfusion physiology on the derivation of theV E /VCO 2 slope.
4,6 -9 Although PaCO 2 is taken as a cross-sectional measurement, whereas thė V E /VCO 2 slope is quantified as a continuous variable, we suggest that breath-to-breath variability in PaCO 2 (i.e. negligible compared with inter-breath variability in P ET CO 2 ) would not have an appreciable effect on the relationships demonstrated in this study.
We acknowledge that beta-blocker selectivity may potentially impact the interpretation of theV E /VCO 2 slope in HFrEF. 26 This , standardized beta; CI, confidence interval; DLO 2 , estimated pulmonary diffusing capacity for oxygen; HCO − 3 , bicarbonate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; PaO 2 , arterial oxygen tension; PAO 2 , alveolar oxygen tension; PA-aO 2 , alveolar-to-arterial O 2 gradient; PACO 2 , alveolar carbon dioxide tension;V A , alveolar ventilation; V D , physiological dead space;V D , V D ventilation. Data are model parameters from univariate linear regressions predicting the ventilatory equivalent for carbon dioxide (V E /VCO 2 ) slope from rest to peak exercise in HFrEF (n = 32) or HFpEF (n = 27). study was not powered to test the effect of beta-blocker selectivity on its outcomes and therefore additional studies are needed to clarify the potential role of beta-blocker selectivity on exercise ventilation in HF. The immediate translation of these data to a specific therapeutic strategy to improve ventilatory efficiency in HF is also not yet available. However, based on recent observations in HFpEF, which suggest that exercise training attenuates the pathological processes of skeletal muscle remodelling (leading to improved oxidative metabolism 27 ) and exercise accompanied by inorganic nitrite supplementation improves central-peripheral haemodynamics (e.g.V A /Q ∼1.0), 12, 28 we hypothesize that questions tested in this study applied to those paradigms can be used to advance understanding of how theV E /VCO 2 slope should be interpreted, while also lending an ability to properly manage ventilatory function in HF. Lastly, our suggestion of a possible role of impaired skeletal muscle afferents in abnormal ventilatory control that contributes to an increasedV E /VCO 2 slope in HFpEF has not been formally tested in the setting of the present aims. However, because of skeletal muscle pathophysiology (e.g. a shift from type I to II fibres 20 ), HFpEF may be predisposed to abnormal skeletal muscle afferent function similar to that recognized in HFrEF.
18,19,21
Conclusions
These data suggest that patients with HF demonstrate an abnormally increasedV E /VCO 2 where at standard body temperature of 37 ∘ C and pHa at 7.4, s equals 0.0307 mmol/L/mmHg, which is the plasma solubility coefficient of CO 2 , whereas pK' equals 6.0907, which is the acid-dissociation constant of carbonic acid. 29, 30 Both s and pK' were corrected for temperature (T) and pHa as follows 29, 30 : Base excess of arterialized blood (BE) was calculated using the Van Slyke equation derived by Siggaard-Andersen from BE and buffer base curves at body temperature and corrected for SaO 2 22,23 : vs. pHa plot equal to 7.7 + 1.43 × Hb, and the final bracketed term is to correct for differences in SaO 2 from ideal oxygenation at 1.0.
Derived alveolar gas and air equation parameters. By using arterial blood gas measurements and acquired basic ventilation and gas exchange responses, 'ideal' alveolar gas and air equations and associated parameters could be used to calculate the following in addition to V D /V T (as explained in Methods) 4, 6, 7, 9, 10 : alveolar ventilation and volume, 
